Estimated to cost up to 440 bEUR
Neuropathic pain affects up to 10% of the population in Europe and the US. It has highly detrimental effects on quality of life, impairing everyday activities, social functioning as well as physical well-being. Neuropathic pain can be so severe that some patients are not even able to wear regular clothes.
Market growth is driven by a globally ageing population with an increasing prevalence of chronic diseases such as Type 2 diabetes, which is one common cause of neuropathic pain. Other common causes are injuries, chemotherapy and shingles.
Insufficient treatments, life-threatening side effects
Current standard of care treatments for neuropathic pain was originally developed for epilepsy or depression such as pregabalin, gabapentin, duloxetine and amitriptyline.
These treatments provide only partial painrelief and are associated with significant safety and tolerability issues such as abuse potential and suicidality.
Conventional opioid compounds, such as morphine and oxycodone, are very useful in treating acute pain, but they are much less effective against chronic pain including neuropathic pain, and they are not officially recommended by national advisory bodies.
Also, conventional opioids that affect the mu-opioid receptor (MOR) have significant, possibly life-threatening sideeffects (respiratory depression) and comes with abuse potential. Patients treated with conventional opioids quickly become tolerant to their analgesic (pain-reducing) effect, necessitating increased doses with an increased risk of toxicity. Furthermore, the euphoric effects of classical opioids like morphine have resulted in an epidemic of opioid overuse, particularly in the US, leading to thousands of deaths and costing health services billions of dollars which have led to multiple lawsuits against Big Pharma companies.
The drug candidate PN6047 does not affect the mu-opioid receptor. Instead, it selectively activates the delta opioid receptor (DOR) in the endogenous opioid system and is expected to provide safe and effective relief of neuropathic pain with no abuse potential. The drug candidate PN6047 has the potential to be first-in-class.
The estimated direct and indirect health care costs for neuropathic pain disorders in the EU vary between 2 and 3% of GDP. In 2016, this estimate would result in a cost of up to 440 bEUR. Introducing an effective and safe treatment for neuropathic pain would save the member states high costs and improve the quality of life for their people.
